Application of PPAR (peroxisome proliferators-activated receptor) gamma cytokine to preparation of hepatic failure treatment drug

A liver failure and cytokine technology, applied in the fields of clinical medicine, molecular medicine and biomedicine, can solve the problems of death of patients and shortage of donor livers

Inactive Publication Date: 2019-09-27
杭州笙源生物科技有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But due to a severe shortage of donor livers, a large ...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of PPAR (peroxisome proliferators-activated receptor) gamma cytokine to preparation of hepatic failure treatment drug
  • Application of PPAR (peroxisome proliferators-activated receptor) gamma cytokine to preparation of hepatic failure treatment drug
  • Application of PPAR (peroxisome proliferators-activated receptor) gamma cytokine to preparation of hepatic failure treatment drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Embodiment 1: Injection containing PPARγ cytokines treats a large animal (young pig) model of liver failure

[0044] Animal model: 30 male Chinese young pigs (8-10 kg) were randomly divided into two groups, 15 in each group. Each young pig was injected with D-gal 1.5g / kg in the jugular vein to create a liver failure model.

[0045] Test group: Multiple intravenous injections of PPARγ injection at fixed time points after D-gal injection, dose: 10ml / kg, twice a day.

[0046]Control group: inject the same amount of normal saline without PPARγ.

[0047] Neither the control group nor the experimental group received other drug treatment.

[0048] figure 1 It is a schematic diagram of the survival time curves of the young pigs of the experimental group and the control group, showing the survival rate of the young pigs of the experimental group and the control group. The results showed that the 3-day survival rate of young pigs in the treatment group containing PPARγ cytoki...

Embodiment 2

[0049] Example 2: The small animal (rat) model of liver failure treated by lyophilized powder injection containing PPARγ cytokine

[0050] Animal model: 100 male rats (200-250 g) were randomly divided into two groups, 50 in each group. Each rat was intraperitoneally injected with D-gal 1.5g / kg to make a liver failure model. The PPARγ freeze-dried powder and water for injection are prepared into a suspension.

[0051] Experimental group: 4 ml of PPARγ freeze-dried powder suspension was injected intraperitoneally at a fixed time point after D-gal injection, twice a day.

[0052] Control group: inject the same amount of normal saline without PPARγ.

[0053] Both the control group and the experimental group received no other drug treatment.

[0054] figure 2 Schematic diagram of the survival time curves of rats in the experimental group and the control group, figure 2 The survival rates of rats in the experimental group and the control group were shown: the results showed t...

Embodiment 3

[0055] Embodiment 3: The suspension containing PPARγ cytokine treats the rabbit model of liver failure

[0056] Animal model: 40 adult male rabbits (2000-2500 g) were randomly divided into two groups, 20 in each group. Each rabbit was intramuscularly injected with D-gal 1.5g / kg to make a liver failure model.

[0057] Test group: intramuscular injection of 20 ml of PPARγ suspension at fixed time points after D-gal injection, twice a day.

[0058] Control group: inject the same amount of normal saline without PPARγ.

[0059] Both the control group and the experimental group received no other drug treatment.

[0060] image 3 It is a schematic diagram of the survival time curves of rabbits in the experimental group and the control group, image 3 The survival rate of the rabbits in the experimental group and the control group is expressed: the results show that the survival rate of the rabbits in the PPARγ treatment group is 90% at 1 day, 90% at 7 days, and 90% at 14 days, wh...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of a PPAR (peroxisome proliferators-activated receptor) gamma cytokine to preparation of a hepatic failure treatment drug. The drug comprises a pharmaceutically acceptable excipient, antioxidant and carrier of the PPAR gamma cytokine. The problem that a large number of hepatocytes are dead in the course of hepatic failure can be solved by the PPAR gamma cytokine. PPAR gamma JNK (jun n-terminal kinase) is one of family members of MAPK, and a JNK pathway can inhibit hepatocyte apoptosis by regulating and controlling expression of PPAR gamma. Besides, damage of the liver and other organs is further aggravated due to the fact that serious liver metabolism dysfunction can appear in the hepatic failure process. PPAR gamma plays a pivotal role in lipid metabolism, and researches show that a PPAR gamma deficient type neonatal mouse has severe lipodystrophy shortly after birth.

Description

technical field [0001] The invention belongs to the fields of clinical medicine, molecular medicine and biomedicine, and is a new technology for treating liver failure with PPARγ cytokine series drugs, specifically, the application of a PPARγ cytokine in the preparation of medicaments for treating liver failure. Background technique [0002] Liver failure is a kind of disease caused by extensive necrosis of the liver caused by various reasons. Except for orthotopic liver transplantation, there is currently no specific treatment. However, due to the severe shortage of donor livers, a large number of patients died while waiting for liver transplantation. Clarifying the pathogenesis of liver failure and early treatment targeting the mechanism can effectively block the progression of the disease and reduce the mortality rate, which is of great significance to the treatment of liver failure. [0003] Peroxisome proliferator-activated receptor gamma (PPARγ) is a member of the ty...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/19A61P1/16
CPCA61K38/19A61P1/16
Inventor 李君陈新李江石东燕
Owner 杭州笙源生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap